Advanced prostate cancer treatment is increasingly personalized. Rather than relying on one treatment approach for every patient, medical oncologists consider factors such as disease stage, hormone sensitivity, previous treatment, imaging findings, and molecular biomarkers when determining which therapies may be appropriate.
Treatment can include androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), PSMA-targeted radioligand therapy, and biomarker-directed drugs such as PARP inhibitors. These treatments work in different ways and may be used alone or as part of a broader treatment strategy depending on the individual cancer and its treatment history.
At Wellness Oncology and Hematology, we provide medical oncology care in Tarzana and West Hills for patients throughout Woodland Hills, Encino, and the West San Fernando Valley. Our team evaluates the characteristics of the cancer and the patient’s previous treatment before discussing which prostate cancer treatment options should be considered.
Androgen Deprivation Therapy (ADT) and Advanced Hormone Blockade
Prostate cancer cells often depend on androgens, including testosterone, for signals that support their growth. Because of this, hormone-based treatment remains an important component of care for many patients with advanced or metastatic prostate cancer.
How Hormone Therapy Slows Hormone-Driven Prostate Cancer
Androgen deprivation therapy reduces androgen stimulation of prostate cancer. Depending on the treatment plan, ADT may involve medications that act on the hormonal signaling system, including luteinizing hormone-releasing hormone (LHRH) agonists or antagonists.
ADT can be used in different advanced prostate cancer settings and may be combined with other systemic therapies. The appropriate approach depends on factors such as the extent of disease, previous treatment, overall clinical circumstances, and whether the cancer remains sensitive to hormone suppression.
For patients receiving prostate cancer care in Tarzana or West Hills, an oncology consultation can help determine whether ADT should be part of the treatment strategy and whether additional therapy should be considered.
Second-Generation Androgen Receptor Pathway Inhibitors
Some prostate cancers continue to use androgen receptor signaling even when testosterone has been substantially reduced. Androgen receptor pathway inhibitors interfere with this pathway at different points.
Examples include enzalutamide, abiraterone, apalutamide, and darolutamide. These medications are generally taken orally and may be combined with ADT depending on the disease setting and treatment plan.
The appropriate medication and combination can vary according to whether the cancer is hormone-sensitive or castration-resistant, whether it has metastasized, and which treatments the patient has already received. These distinctions are important because medications within this broader treatment category do not all work in exactly the same way or apply to every clinical situation.
Also Read: New Development in Prostate Cancer Treatment: Wellness Oncology & Hematology: Oncologists
PSMA Radioligand Therapy for Advanced Prostate Cancer
PSMA radioligand therapy is a targeted approach used for selected patients with advanced prostate cancer. It uses a molecular target found on many prostate cancer cells to deliver therapeutic radiation to PSMA-expressing cancerous tissue.
What Is PSMA?
PSMA stands for prostate-specific membrane antigen, a protein frequently found at high levels on prostate cancer cells. Its presence can be evaluated with specialized imaging, including PSMA-targeted PET imaging.
PSMA can serve different roles in prostate cancer care. PSMA-targeted imaging can help identify and evaluate disease, while PSMA-targeted radioligand therapy uses the biological target to deliver therapeutic radiation to PSMA-expressing cancer cells in appropriately selected patients.
How PSMA Radioligand Therapy Targets Prostate Cancer Cells
PSMA radioligand therapy combines a PSMA-targeting molecule with a therapeutic radioisotope. Pluvicto uses lutetium-177, allowing radiation to be delivered to PSMA-positive cancer cells and metastatic sites.
The treatment is administered intravenously, with the treatment schedule determined by the applicable clinical indication and the patient’s individual treatment plan. Because this approach depends on PSMA expression, appropriate imaging and clinical evaluation are important when determining whether PSMA-targeted treatment should be considered.
Eligibility for PSMA radioligand therapy depends on the current treatment indication as well as the patient’s disease characteristics, PSMA expression, previous therapies, and other clinical factors. A medical oncologist can review the patient’s imaging, pathology, and treatment history to determine whether this approach may be appropriate.
Biomarker-Driven Treatment and PARP Inhibitors
Modern prostate cancer treatment increasingly incorporates molecular information. Genetic and genomic testing can identify alterations that may help guide treatment selection, particularly in advanced or metastatic disease.
Genetic Testing for BRCA and HRR Gene Alterations
Some prostate cancers contain alterations in genes involved in homologous recombination repair (HRR), a pathway involved in repairing damaged DNA. BRCA1 and BRCA2 are among the genes that may be evaluated.
Tumor genomic testing, which may involve next-generation sequencing, can identify certain molecular alterations. Depending on the clinical setting, testing may also include inherited, or germline, genetic evaluation.
Finding an actionable biomarker does not automatically determine which treatment a patient will receive. Instead, the result provides additional information that the oncology team can consider alongside the disease setting, treatment history, and other clinical factors.
PARP Inhibitors for Advanced Prostate Cancer
PARP inhibitors target a pathway involved in DNA repair. In cancers with certain DNA-repair defects, blocking PARP activity can interfere with the cancer cell’s ability to repair damage and survive.
Examples of PARP inhibitors used in appropriate prostate cancer settings include olaparib and rucaparib. Their use depends on the specific biomarker, disease setting, previous treatments, applicable regulatory indications, and individual patient factors.
For patients with advanced prostate cancer, genomic testing and a detailed review of the cancer’s molecular profile can help determine whether a PARP inhibitor or another biomarker-directed treatment should be considered.
Also Read: Why Everyone Seems to Have Cancer: Wellness Oncology & Hematology: Oncologists
How Advanced Prostate Cancer Treatments Differ
Several major treatment approaches may be considered during advanced prostate cancer care, but they do not target the disease in the same way.
| Treatment | How It Works | General Clinical Role | Administration |
|---|---|---|---|
| Androgen Deprivation Therapy (ADT) | Reduces androgen stimulation of prostate cancer | Used across appropriate hormone-sensitive and advanced prostate cancer settings | Hormonal treatment determined by the prescribed regimen |
| Androgen Receptor Pathway Inhibitors (ARPIs) | Interfere with androgen production or receptor-pathway signaling | Used in appropriate hormone-sensitive and castration-resistant settings | Many agents are taken orally |
| PSMA Radioligand Therapy | Uses PSMA targeting to deliver therapeutic radiation | Selected patients with PSMA-positive advanced prostate cancer who meet applicable treatment criteria | Intravenous radioligand treatment |
| PARP Inhibitors | Interfere with DNA repair through PARP inhibition | Selected prostate cancers with relevant molecular characteristics | Many agents are taken orally |
This comparison is an educational overview rather than a guide for choosing treatment. Eligibility, combinations, and treatment sequencing depend on disease characteristics, biomarker results, previous therapies, and the applicable treatment criteria.
How Is an Advanced Prostate Cancer Treatment Plan Developed?
Choosing among ADT, androgen receptor pathway inhibitors, PSMA-targeted treatment, PARP inhibitors, and other therapies begins with understanding the cancer itself. The treatment plan may also change over time as the disease responds to therapy or its characteristics change.
Step 1: Diagnostic and Genomic Evaluation
Evaluation may include disease staging, laboratory testing, pathology review, imaging such as PSMA PET when appropriate, and tumor or germline biomarker testing when indicated.
These findings help the oncology team understand the extent and characteristics of the disease and identify molecular alterations that may influence treatment options.
Step 2: Treatment Selection
The oncology team can then consider whether treatment should include ADT, an androgen receptor pathway inhibitor, PSMA-targeted therapy, a biomarker-directed treatment, or another appropriate approach. Combination strategies may also be considered when clinically appropriate.
The goal is not simply to select the newest treatment. It is to identify therapies that fit the current disease setting, previous treatment, molecular findings, and individual clinical circumstances.
Step 3: Treatment and Ongoing Monitoring
Prostate cancer treatment requires ongoing assessment. Depending on the therapy and disease setting, monitoring may include PSA testing, other laboratory studies, imaging, assessment of treatment response, and evaluation of side effects.
These findings can help the oncology team determine whether the current treatment remains appropriate or whether the treatment strategy needs to change.
Step 4: Symptom and Quality-of-Life Management
Managing advanced prostate cancer involves more than treating the cancer itself. Care may also address symptoms, treatment side effects, bone health, physical function, and overall quality of life.
These considerations remain important throughout treatment, particularly when patients receive systemic therapy over an extended period.
Individualized Prostate Cancer Care in Tarzana and West Hills
At Wellness Oncology and Hematology, we provide medical oncology care focused on evidence-based treatment and individualized cancer management. For patients with advanced prostate cancer, treatment planning may incorporate disease stage, previous therapies, imaging findings, molecular characteristics, and treatment goals.
Our Tarzana and West Hills locations serve patients from Woodland Hills, Encino, and communities throughout the West San Fernando Valley. Having oncology care close to home can make ongoing evaluation, treatment, and monitoring more accessible throughout the course of care.
Also Read: What Happens After a Cancer Diagnosis? Understanding Your First Oncology Appointment
Frequently Asked Questions
What Is the Difference Between ADT and Targeted Therapy for Prostate Cancer?
Androgen deprivation therapy reduces androgen stimulation that can support prostate cancer growth. Targeted treatments are selected based on particular biological characteristics of the cancer. PSMA radioligand therapy, for example, targets PSMA-expressing prostate cancer cells, while PARP inhibitors may be appropriate for cancers with certain DNA-repair alterations. Depending on the disease setting, these treatments may be used alongside other therapies rather than as interchangeable alternatives.
How Does PSMA Therapy Target Prostate Cancer Cells Throughout the Body?
PSMA is a protein found at high levels on many prostate cancer cells. PSMA radioligand therapy uses a targeting molecule that binds to PSMA and carries a therapeutic radioactive isotope, such as lutetium-177, to PSMA-positive cancer cells and metastatic sites. Appropriate imaging and clinical evaluation are used to determine whether PSMA-targeted treatment may be considered.
Who May Be a Candidate for PSMA Radioligand Therapy?
Eligibility depends on factors including the type and stage of prostate cancer, PSMA expression on appropriate imaging, previous treatment, overall clinical circumstances, and the current treatment indication. A medical oncologist can review imaging, pathology, treatment history, and other clinical information to determine whether PSMA radioligand therapy may be appropriate.
How Can Genetic Testing Help Determine Whether a PARP Inhibitor May Be an Option?
PARP inhibitors interfere with a cancer cell’s ability to repair certain types of DNA damage. Some prostate cancers contain alterations in BRCA or other homologous recombination repair genes that may influence whether a PARP inhibitor should be considered. Genomic or genetic testing can identify these alterations, but eligibility and expected benefit depend on the specific finding and clinical circumstances.
What Happens When Prostate Cancer Becomes Resistant to Initial Hormone Therapy?
When prostate cancer continues to progress despite testosterone suppression, it may be classified as castration-resistant prostate cancer. This does not mean treatment options have been exhausted. Depending on the disease characteristics and previous therapies, the oncology team may consider additional androgen receptor pathway treatment, chemotherapy, PSMA-targeted radioligand therapy, PARP inhibitors for patients with appropriate biomarkers, or other available approaches.
What Should I Bring to a Prostate Cancer Consultation?
If available, bring relevant pathology reports, imaging results, PSA history, a current medication list, genetic or genomic testing results, and records of previous cancer treatments. Having this information available can help the oncology team understand the history of the disease and evaluate which treatment options may warrant discussion.
Discuss Your Prostate Cancer Treatment Options
Advanced prostate cancer treatment increasingly depends on the biology and history of the individual cancer. Disease stage, hormone sensitivity, previous treatment, PSMA expression, imaging findings, and genomic results can all influence which therapies should be considered.
At Wellness Oncology and Hematology, we provide individualized medical oncology care in Tarzana and West Hills for patients throughout the West San Fernando Valley. Schedule a consultation with our team to review your diagnosis, previous treatment, testing results, and the prostate cancer treatment options that may be appropriate for your current clinical situation.
This article provides general educational information and is not a substitute for individualized medical advice. Treatment eligibility, sequencing, and outcomes vary according to the patient’s diagnosis and clinical circumstances.